2,4-thiazolidinedione has been researched along with Leukemia, Erythroblastic, Acute in 1 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirase, N | 1 |
| Yanase, T | 1 |
| Mu, Y | 1 |
| Muta, K | 1 |
| Umemura, T | 1 |
| Takayanagi, R | 1 |
| Nawata, H | 1 |
1 other study available for 2,4-thiazolidinedione and Leukemia, Erythroblastic, Acute
| Article | Year |
|---|---|
Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562.
Topics: Cell Differentiation; Erythrocytes; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Ligands; Nu | 2000 |